We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Of the 42 million people with AIDS around the world, less than 300,000 are receiving proper treatment and 100,000 of those are Brazilian.

Prior to 1997, Brazil's AIDS programme kept costs down by ignoring patents from western companies, producing generic copies of those patented drugs. In 1997 Brazil agreed to comply with World Trade Organisation rules. But it continues to threaten to strip patents on newer drugs, thereby pressuring pharmaceutical companies to lower their prices on AIDS drugs.

In this article Roger Bate, director of the organisation Africa Fighting Malaria, argues that Brazil's approach to AIDS treatment is not sustainable. And he cautions against African countries from contemplating copying its approach, saying that – with the possible exception of South Africa – these nations lack the political will, technical competence and health infrastructure to replicate Brazil's apparent success.

Link to full Tech Central Station article